Revance Releases First Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Revance Therapeutics (RVNC) Tops Q1 EPS by 12c
May 9, 2016 5:04 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More